Mice treated with SHO1122147 had no significant change in liver mass but showedimprovements in fatty liver disease phenotypes including decreasedplasma alanine aminotransferase (ALT) and decreased liver triglycerides(Figure 7A–C).Hepatopathological assessment of fixed liver samples revealed a significantdecrease of the MAFLD activity score that was primarily due to decreasedhepatic steatosis (Figured 7D–G). The gene discussed is GPT; the disease is steatosis.